|
Entire pharma supply chain under one roof
|
|
Anurag More, Mumbai
April 01 , 2015
|
|
|
CPhI South East Asia 2015, in its fourth edition, is known as a place where companies can meet ASEAN decision-makers and business partners within the pharmaceutical industry with a potential of US$80 billion pharmaceutical market value at retail price in 2017. The show will be held from April 8-10, 2015, at Jakarta International Expo, Indonesia.
The event brings the entire pharmaceutical supply chain under one roof, making it the only comprehensive show for ASEAN (Association of Southeast Asian Nations) pharma solutions. The event is being organised by UBM EMEA, co-located with P-MEC South East Asia and InnoPack.
Highlights of the event
- An integrated conference platform;
- A ‘Supplier Finder Programme’;
- A new report created by CPhI in collaboration with Global Business Reports entitled ‘Indonesian 2015 Pharmaceuticals Perspectives.’
The exclusive report contains a comprehensive collection of analyses, facts, figures, exclusive interviews with leading CEOs and associations, and expert opinion articles that provide in-depth perspectives on issues and challenges facing the Indonesia pharmaceutical sector and the global market.
The Supplier Finder Programme enables exhibitors to connect with potential business partners in just a few seconds – a time-efficient aid that helps you to find the right partner. Key topical insights to come out of the conference platform include ‘Healthcare Plans across South East Asia’ and ‘Roadmap of Indonesian Pharmaceutical Industry 2015 – 2025.’
Visitors
According to the organisers, “The number of visitors are expected to mirror last year’s show, which was the most successful event to date with 6,000 attendees. What is more notable, however, is the huge increase in the geographic spread of exhibitors this year with 38 countries represented, significantly improving on the 23 countries seen in 2014.”
“This shift in the event’s global presence is a key marker and demonstrates the rising significance that the Indonesian pharma economy is having. As such, it is essential that there is a mechanism to aid new business meetings, both for domestic and international suppliers and CPhI South East Asia has been designed to act as the regional hub to facilitate all new opportunities within the region.”
Exhibitors
This year 240 exhibitors will be present at CPhI South East Asia, mirroring the figures seen in 2014, which was a record-breaking year.
Focussing on India there would be 18 companies from India who would be exhibiting at this year’s event and in the future this is expected to grow with the importation of raw materials and in particular, the potential growth in generics consumption. The event gives immense opportunity to Indian companies who are looking at this market to become an early entrant and gain a foothold within the country.
Pavilions at the event
Talking about a pavilion in the email interaction spokesperson from the organiser said, “This year there are various country pavilions presented at CPhI South East Asia. Among these are the MENSA Group, a China Pavilion and a Korean Pavilion. Key exhibitors from leading pharma economies include USA, India, Japan and China.”
Workshops, seminars and conferences
There are extensive conference programme for 2015 will cover key topics, which have been designed specifically to assist companies in identifying growth areas within this market. These include:
Roadmap of Indonesian Pharmaceutical Industry, 2015 – 2025
Indonesian Pharmaceutical Industry in ASEAN - Economic Community 2015: Where do we stand?
The Chances for Halal Drugs in the ASEAN Market
ASEAN Roundtable - Portrait of Pharma Industry: Opportunities & Challenges Indonesian Pharmaceutical Association, MOPI/PhaMA, SAPI, Thailand, Philippines and Vietnam.
Healthcare Plans across South East Asia
3 Pharma events in 1
CPhI South East Asia brings Pharma Ingredients professionals from over 140 countries and regions to attend this unique environment where delegates can meet, learn, network and share ideas with each other. Here your company has the ability to gain access to the ASEAN pharma market where they will meet potential partners and identify business opportunities in the region's rapidly expanding market.
P-MEC showcases innovative pharmaceutical machinery, laboratory equipment and analytical technology through face to face networking and education. Government funding of finished dosage and generics continue to drive rapid growth in the manufacture base throughout South East Asia, requiring infrastructure investment and machinery to meet the demand. P-MEC brings the well-known pharma machinery event from Europe, India and China to CPhI South East Asia to build the industry.
InnoPack brings the latest innovations in packaging and drug delivery systems to pharmaceutical buyers. Covering packaging, drug delivery systems, labelling and track & trace, InnoPack joins CPhI South East Asia to showcase global packaging solution providers. Packaging is increasingly important to the pharma supply chain, playing a key role in product development, safety, dosage and dispensing.
South East Asian pharmaceutical market overview
The pharmaceutical market for the ASEAN region is composed of the established and the emergent economies. The established economies include South Korea, Taiwan and Singapore, the emergent economies include Indonesia, Thailand, the Philippines, Malaysia and Vietnam.
Overall, the region is classed as emergent with considerable potential for growth in the economies of Indonesia, Thailand and the Philippines due to larger populations and steadily growing economies that are witnessing rising wages and the prioritising of healthcare by regional governments.
In recent years these markets have become very attractive to foreign investment and joint-ventures with multinationals due to improvements in manufacturing standards through effective national regulation.
As per the reports shared by the organiser, “Last year, the Indonesian pharma industry was valued at $6.5 billion following tremendous growth from 2007 to 2013 when the industry grew by 85% and total healthcare spending is predicted to reach $21.7 billion by the end of 2015. The only challenge observed, is that many domestic manufacturers are already operating at capacity and are actively searching for international investment to sustain their exponential growth potential.”
“The composition of Indonesia’s pharma industry continues to evolve and expand. The election of president Jokowi is forecast to have a positive influence on the pharma economy as the Indonesian government has historically bestowed minimal funds to the healthcare sector compared to neighbouring countries. As such, healthcare expenditure is forecast to double by 2018 and an initiative - Jaminan Kesehatan Nasional (JKN) - to improve accessibility to healthcare is already underway. The programme is expected to run for five years, providing access to drugs for a forecasted population of 257.5 million by 2019 and will create a huge demand for prescription generics as the government takes on the financial burden of drug sourcing. As a consequence, in the medium term, this rise in prescription generic demand will come into play as over the counter (OTC) demand – which has increased steeply over recent years – becomes progressively more linear once government initiatives are implemented.”
“In the short-term, OTCs will remain in high demand due to a gentrified and growing middle-class population who are more health-conscious, resulting in a rise in OTC consumption. In fact, the Indonesian government plans to increase GDP per capita from $3000 to $15,000 by 2025, highlighting the potential explosive growth in disposable incomes.”
Key driving economy
With positive, influential changes continually shaping the pharma industry, Indonesia is set to emerge as one of the world’s most dynamic markets for pharmaceuticals and the key driving economy within the ASEAN region.
CPhI South East Asia is integral to this burgeoning market and provides direct access to the thriving ASEAN pharmaceutical market that continues to grow year-on-year. Indonesia is projected to be the fastest-growing ASEAN economy and is attracting more and more global pharma players, making this the perfect location – and crucially, time - for international buyers and suppliers to meet and break into this dynamic market.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|